Last updated: March 16, 2026
What is the drug associated with NDC 24208-0023?
NDC 24208-0023 refers to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved for spinal muscular atrophy (SMA) in pediatric patients under 2 years of age. Approved by the FDA in 2019, Zolgensma is a one-time intravenous infusion aimed at replacing defective or missing copies of the survival motor neuron 1 (SMN1) gene.
What is the current market size for Zolgensma?
The global SMA treatment market was valued at approximately $650 million in 2022. The SMA gene therapy segment accounts for about 80% of that market, with Zolgensma representing the primary revenue driver.
- U.S. Market Penetration: Covered by private insurers and Medicaid; SNOMED-CT estimates patient population at approximately 600-1,000 infants annually.
- Global Reach: Limited primarily to North America and select European countries; some approval in Japan and Latin America.
- Pricing: List price is approximately $2.125 million per dose.
How is the pricing of Zolgensma structured?
The list price of Zolgensma is $2.125 million, set to recover the high costs of gene therapy development and manufacturing. Payers often negotiate discounts or installment payment options, given the therapy's high upfront cost.
- Per Dose Cost: $2.125 million
- Cost Recovery: Price reflects R&D, manufacturing complexity, and rarity of SMA.
- Payment Models: Installment plans over three years, outcome-based payments in some contracts.
What are the key factors influencing Zolgensma's market growth?
- Market Penetration: Expansion in neonatal screening programs increases eligible patient count.
- Pricing Policies: Government negotiations and insurance reimbursements influence net revenues.
- Competitive landscape: Spinraza (nusinersen) and Evrysdi (risdiplam) hold larger market shares, with Zolgensma targeting early intervention.
- Regulatory expansions: In Europe and Asia, approvals will influence demand.
- Manufacturing capacity: Limited manufacturing facilities may lead to supply constraints.
What are projections for revenue growth?
| Year |
Estimated Global Revenue |
Notes |
| 2023 |
$1.2 billion |
Growth driven by increased coverage, global approvals, and newborn screening programs |
| 2024 |
$1.5 billion |
Expanded access in Europe, Japan, and Latin America |
| 2025 |
$1.8 billion |
Additional approvals and insurance coverage expansions |
Revenue growth depends on the adoption rate among the neonatal screening-identified population, pricing negotiations, and supply chain scalability.
How might pricing evolve?
- Pressure from payers: As more therapies enter the SMA space, Zolgensma could face pressure to reduce prices or reformulate payment structures.
- Manufacturing costs: Advances in production may lower costs, enabling possible price reductions.
- Regulatory decisions: Approvals for broader age ranges (e.g., older children and adults) could expand market size, affecting pricing strategies.
Risks and uncertainties
- Market competition: Widespread adoption of existing treatments like Spinraza and Evrysdi could diminish Zolgensma's market share.
- Reimbursement policies: Changes in healthcare policy, especially in the U.S., could impact revenue.
- Manufacturing constraints: Limited production capacity may restrict growth potential.
- Pricing pressure: Rising costs of gene therapy development and manufacturing could keep prices high, but payers may resist high prices as therapies mature.
Key Takeaways
- NDC 24208-0023 corresponds to Zolgensma, a high-cost gene therapy for SMA.
- The therapy's list price is $2.125 million per dose, with revenue projections reaching up to $1.8 billion globally by 2025.
- Market expansion depends on approvals, neonatal screening efforts, payer reimbursement policies, and manufacturing capacity.
- Competition from earlier therapies and reimbursement negotiations may influence market share and pricing.
- Long-term growth will be shaped by regulatory, manufacturing, and policy developments.
FAQs
1. What factors determine Zolgensma's market penetration?
Market penetration depends on neonatal screening adoption, regulatory approvals outside the U.S., payer reimbursement strategies, and manufacturing capacity.
2. Will the price of Zolgensma decrease over time?
Price reductions are possible if manufacturing costs decrease or if payers negotiate better terms, but the initial high price largely reflects R&D, manufacturing complexity, and market exclusivity.
3. How does Zolgensma compete with Spinraza and Evrysdi?
Zolgensma is a one-time infusion, while Spinraza and Evrysdi are administered repeatedly. Market acceptance depends on patient eligibility, safety profile, and reimbursement dynamics.
4. What impact do approvals in other countries have?
Global approvals extend market reach, increase demand, and could lead to price negotiations influenced by healthcare systems' policies.
5. Are there upcoming regulatory changes that could affect pricing?
Policy shifts aiming for price control on rare disease treatments could influence future pricing and reimbursement strategies.
References
[1] U.S. Food and Drug Administration. (2019). FDA approves Zolgensma for children under two with SMA.
[2] EvaluatePharma. (2022). Biopharma Market Reports.
[3] IQVIA. (2022). National Sales Perspectives.
[4] Novartis. (2023). Annual Report.
[5] Medtech Dive. (2022). Impact of Reimbursement Strategies on Rare Disease Therapies.
